This may explain the benefit of anti–PD-L1 therapy when added to this radiation and cetuximab combination treatment, despite no apparent therapeutic efficacy of anti–PD-L1 when used alone in this immunologically “cold” tumor model. The gene discussed is CD274; the disease is neoplasm.